// App-Quantinova.ai

P558 : The SF-36® Health Survey distinguishes disease burden on functioning and well-being between patients with active vs inactive ulcerative colitis

Researchers

Presenter

  • D.T. Rubin

Principal Investigators

  • J. Pans

  • J.O. Lindsay

  • S. Vermeire

  • A. Yarlas

  • M. Bayliss

  • J.C. Cappelleri

  • S. Maher

  • A.G. Bushmakin

  • L.A. Chen

  • A. Manuchehri

  • P. Healey

Medical Centers

  • University of Chicago, Inflammatory Bowel Disease Center, Chicago, United States

  • Hospital Clinic Barcelona, Barcelona, Spain

  • Institute of Dentistry, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom

  • Department of Gastroenterology , Univ. Hospitals Leuven, Leuven, Belgium

  • Optum, Lincoln, United States

  • Pfizer Groton CT United States

  • New York University School of Medicine, New York, NY

  • Pfizer Inc., Tadworth, United Kingdom

Locations

  • United States

  • Spain

  • United Kingdom

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved